Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2015-12-17

Clinical Trial Update: Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SCH 900435 for schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SCH 900435

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 2 | Status: WITHDRAWN